Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Atvērts

2.75 6.18

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.61

Max

2.81

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+200.8% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-85M 246M
Iepriekšējā atvēršanas cena	-3.43
Iepriekšējā slēgšanas cena	2.75

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. sept. 23:56 UTC

BorgWarner Inc. is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

2026. g. 29. sept. 23:56 UTC

Alexandria Real Estate Equities, Inc. is trading modestly higher in after-market hours following a brief gain after Tuesday's close, despite recent lower closes.

2026. g. 29. sept. 23:56 UTC

Shift4 Payments, Inc. is trading modestly higher in after-market hours, recovering from an initial dip to settle at 0.59%, below its 20-day moving average.

2026. g. 29. sept. 23:56 UTC

Correlated Moves

Southern Copper Corp is trading higher in after-market hours, supported by gains in the NYLIM FTSE International Equity Currency Neutral ETF amid fluctuating market conditions.

2026. g. 29. sept. 23:56 UTC

Correlated Moves

Brixmor Property Group Inc traded higher in after-market hours, reflecting a slight uptick amid a modest recovery in Regency Centers Corp.

2026. g. 29. sept. 23:56 UTC

Houlihan Lokey Inc is trading higher in after-market hours, despite remaining below its 20-day moving average and near the lower end of its one-month range.

2026. g. 29. sept. 23:56 UTC

In after-market trading, Donaldson Company Inc is slightly higher since Tuesday's close, with a cumulative return peaking at 0.11%.

2026. g. 29. sept. 23:56 UTC

IDEX Corp's shares have advanced modestly in after-market trading, supported by strong buying interest and remaining above its 20-day moving average.

2026. g. 29. sept. 23:56 UTC

Columbia Sportswear Co's shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. g. 29. sept. 23:56 UTC

Correlated Moves

Columbia Banking System Inc. is moving higher in after-market trading, supported by Verizon Communications' new board member announcement and overall market strength.

2026. g. 29. sept. 23:56 UTC

The Canadian dollar advanced against the Swiss franc, supported by a decline in U.S. job openings, remaining near the upper end of its one-month trading range.

2026. g. 29. sept. 23:55 UTC

Trane Technologies PLC declined in after-market trading, dipping shortly after 6:00 PM but remaining above its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

CVR Energy Inc experiences routine after-market trading with a slight increase, remaining near the upper end of its one-month range.

2026. g. 29. sept. 23:55 UTC

Service Corporation International is trading modestly higher in after-market hours, despite remaining below its 20-day moving average amid recent economic data on job openings.

2026. g. 29. sept. 23:55 UTC

Dolby Laboratories Inc is higher in after-market trading, having peaked earlier but currently remains below its 20-day moving average and near its one-month range low.

2026. g. 29. sept. 23:55 UTC

In after-market trading, Ryman Hospitality Properties Inc has remained roughly flat, trading within a narrow range around the middle of its one-month trading range.

2026. g. 29. sept. 23:55 UTC

Inspire Medical Systems Inc has gained slightly in after-market hours, currently positioned above its 20-day moving average and near the upper end of its one-month range.

2026. g. 29. sept. 23:55 UTC

Tennant Co. traded roughly flat in after-market hours, experiencing a modest uptick from earlier lows while remaining below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

TDS is declining in after-market hours, marking its sixth consecutive session lower and remaining notably below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

Coca-Cola Co is experiencing a modest gain in after-market trading, currently positioned below its 20-day moving average near the lower end of its one-month range.

2026. g. 29. sept. 23:55 UTC

AutoNation Inc finished after-market hours higher, recovering from a prior decline, though it remains significantly below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

One Liberty Properties Inc is trading lower in after-market hours, positioned near the lower end of its one-month range and below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

EPR Properties saw a modest uptick in after-market trading, remaining roughly flat since Tuesday's close and 1.71% below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

Ryder System Inc is trading modestly higher in after-market hours, recovering from four consecutive sessions of declines, though still below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

Aon PLC experienced a modest decline during after-market hours, trading flat since Tuesday's close and positioned below its 20-day moving average.

2026. g. 29. sept. 23:55 UTC

CHF/JPY is declining as JOLTs Job Openings fell to 7.079 million in August, below expectations, reflecting ongoing labor market challenges.

2026. g. 29. sept. 23:55 UTC

Phillips 66 is trading modestly higher in after-market hours, despite remaining below its 20-day moving average and near the lower end of its one-month range.

2026. g. 29. sept. 23:51 UTC

AGCO Corp is lower in after-market trading, continuing a trend with three consecutive sessions of declines and remaining significantly below its 20-day moving average.

2026. g. 29. sept. 23:51 UTC

Correlated Moves

ManpowerGroup Inc is trading lower in after-market hours, reflecting a slight decline since Tuesday's close amid broader market weakness.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

200.8% augšup

Prognoze 12 mēnešiem

Vidējais 8.167 USD 200.8%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.